About this trial
This study investigates a type of cell, called abnormal clonogenic epithelial cells, in patients with bronchiolitis obliterans syndrome who have had an donor stem cell transplant or a lung transplant. Learning more about clonogenic cells in these patients may help doctors to detect signs of bronchiolitis obliterans syndrome earlier in future patients.
Eligibility criteria
Qualifiers
Allo-HCT recipients undergoing a bronchoscopy at MDACC who consent to undergoing study airway brushings in addition to clinically indicated bronchoscopic procedures (e.g. bronchoalveolar lavage)
5 patients with advanced BOS - forced expiratory volume in one second (FEV1) =< 75% predicted and meeting other National Institutes of Health (NIH) criteria (FEV1/forced vital capacity [FVC] ratio 0.7, presence of air trapping or graft versus host disease [GVHD] of another organ)
Active systemic chronic GVHD with new early airflow obstruction OR
Respiratory viral infection in last three months with resolution of viral symptoms but new airflow obstruction
Disqualifiers
Bronchoscopy performed on emergency basis for life-threatening issues as opposed to routine diagnostic testing
Patient unwilling to give consent for study airway brushings
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Medical Chart Review
Treatment groups
Sponsors and collaborators
M.D. Anderson Cancer Center
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator